Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an exclusive TODAY interview.

As someone who had built her career on grit and hard work, Williams hesitated before exploring weight-loss medications ...

For reasons that remain unclear, kidney cancer risk was higher in users of GLP-1 agonists, particularly those under 65 and those who were overweight versus obese.< Patients taking GLP-1 agonists for ...

Tricare officials said the Defense Health Agency is eliminating coverage for its Tricare for Life beneficiaries and others to ...

GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

Columnist Teri Sforza writes that studies have found that semaglutide reduced alcohol intake, binge drinking and relapse ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...